
US independent pharmacy | See the work behind the margin
A prescription can be dispensed successfully while leaving its owner with a difficult business question. Which work consumed the margin? Was the pressure an acquisition cost, a contract term, a rejected transaction or a task repeated three times? For an independent US pharmacy, we want medicines intelligence to make that question inspectable, without treating professional care as a commodity or pretending one national benchmark explains the shop.
In development · Intended scope and questions for evaluation
The organisation.
The people around it.
The United States, India, Australia and Singapore reading routes explore questions for local evaluation. They do not establish overseas deployment, contracts or transferable clearance.
The people involved
Health systems, pharmacy organisations, payers and research partners in separately assessed jurisdictions.
The dependencies
Local providers, pharmacies, payers, professional reviewers, regulators, commissioners and source-rights owners as applicable.
What to examine
Local intended use, evidence applicability, data permissions, contracting, funding and the evaluation and assurance route.
An illustrative set of programme relationships. The actual participants, authority, funding and permissions must be established for the defined setting. Explore every organisation perspective.
Start with the owner’s next decision
The buyer we envisage is an owner, managing pharmacist or small-group operating lead deciding where to spend scarce management attention. A useful first question is whether one recurring exception deserves a process change, a supplier discussion or better documentation. The incentive is a more credible decision about staff time and working capital. It is not a promise that software can renegotiate a payer contract or rescue every unprofitable prescription.
Separate the three prices
An acquisition invoice, a published benchmark and a remittance describe different things. Medicaid publishes National Average Drug Acquisition Cost data as a reference; we would not substitute it for the pharmacy’s own invoices (CMS, n.d.). A proposed review would retain invoice date, product and pack mapping, payment status and later adjustments separately. The owner should be able to see where an apparent margin depends on an incomplete record rather than a real commercial improvement.
A pilot small enough to finish
We propose beginning with one owner-approved operational question and a defined historical sample. The pharmacy would select a short list of frequently investigated products or transaction exceptions. Inputs could include authorised aggregate dispensing counts, purchase records and staff estimates of resolution effort. Identifiable patient data would not be the default requirement. The study would first test whether these records can be reconciled well enough to support the chosen question.
Compare against the review already happening
The comparator should be the owner’s existing spreadsheet, reporting tool or manual review. Both approaches would receive the same frozen sample and the same question. We would measure preparation time, unresolved record mismatches, explanations that a pharmacist can verify and decisions requiring another source. A short independent review of disputed examples would prevent speed from hiding errors. Clinical suitability and dispensing responsibility would remain with the appropriate professionals.
Traceability is a separate obligation
FDA describes package-level tracing under the Drug Supply Chain Security Act (FDA, n.d.). A commercial value review does not establish compliance with those requirements. If a supplier or traceability exception emerges, the output should identify the responsible local process rather than declare a product acceptable. The first discussion therefore needs to distinguish financial investigation from regulated supply-chain tasks and agree which parts are outside the evaluation.
What would make us stop
We would stop or narrow the study if invoices cannot be matched to the selected products, remittances are incomplete, the owner cannot authorise the required data or the review adds more work than it removes. Apparent opportunities that depend on unverified reimbursement assumptions would remain unconfirmed. A useful negative finding might be that a better extract from the existing system solves the problem more cheaply than a new product.
A reason to continue
A next phase would require a repeatable question, an accountable user and evidence that the output changes a real management decision. The commercial discussion would concern a defined review service or controlled software evaluation, with delivery cost and review effort made visible. One pharmacy’s result would not become a national savings claim. Expansion to a small group would require a fresh check of contracts, systems and local working practices.
Sources and reading context
Official source context checked on 13 October 2026. The study design above is a NEUVIOR proposal for discussion, not a reported deployment or result.
FDA | Drug Supply Chain Security Act
CMS (n.d.) Pharmacy Pricing. Available at: https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing (Accessed: 14 October 2026).
FDA (n.d.) Drug Supply Chain Security Act. Available at: https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa (Accessed: 14 October 2026).
Discuss an independent pharmacy review
Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.
Bring the question
your organisation
needs to move.
Tell us where the programme gets stuck, who is affected and what a worthwhile evaluation would help you decide.
Discuss a PHARMORIS evaluationAn initial conversation should describe the organisational question. Agree the purpose and information requirements before sharing records.